305 related articles for article (PubMed ID: 29450330)
1. Aflibercept efficacy in refractory choroidal neovascularization.
Brănişteanu DC; Bîlhă A; Moraru A
Rom J Ophthalmol; 2016; 60(2):96-102. PubMed ID: 29450330
[TBL] [Abstract][Full Text] [Related]
2. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
3. Response to bevacizumab after treatment with aflibercept in eyes with neovascular AMD.
Waizel M; Rickmann A; Blanke BR; Wolf K; Kazerounian S; Szurman P
Eur J Ophthalmol; 2016 Aug; 26(5):469-72. PubMed ID: 27079204
[TBL] [Abstract][Full Text] [Related]
4. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
Pinheiro-Costa J; Costa JM; Beato JN; Freitas-da-Costa P; Brandão E; Falcão MS; Falcão-Reis F; Carneiro ÂM
Ophthalmologica; 2015; 233(3-4):155-61. PubMed ID: 25896317
[TBL] [Abstract][Full Text] [Related]
5. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration.
Yonekawa Y; Andreoli C; Miller JB; Loewenstein JI; Sobrin L; Eliott D; Vavvas DG; Miller JW; Kim IK
Am J Ophthalmol; 2013 Jul; 156(1):29-35.e2. PubMed ID: 23668679
[TBL] [Abstract][Full Text] [Related]
6. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
[TBL] [Abstract][Full Text] [Related]
7. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
[TBL] [Abstract][Full Text] [Related]
8. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
10. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
Cho H; Shah CP; Weber M; Heier JS
Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
Narayan DS; Muecke J
Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes.
Chang AA; Broadhead GK; Hong T; Joachim N; Syed A; Schlub TE; Toth L; Peto T; Zhu M
Ophthalmic Res; 2015; 55(2):84-90. PubMed ID: 26637166
[TBL] [Abstract][Full Text] [Related]
13. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
Rao P; Lum F; Wood K; Salman C; Burugapalli B; Hall R; Singh S; Parke DW; Williams GA
Ophthalmology; 2018 Apr; 125(4):522-528. PubMed ID: 29146306
[TBL] [Abstract][Full Text] [Related]
14. INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results.
de Oliveira Dias JR; Costa de Andrade G; Kniggendorf VF; Novais EA; Takahashi VKL; Maia A; Meyer C; Watanabe SES; Farah ME; Rodrigues EB
Retina; 2019 Apr; 39(4):648-655. PubMed ID: 29232334
[TBL] [Abstract][Full Text] [Related]
15. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.
Cohen MN; Houston SK; Juhn A; Ho AC; Regillo CD; Vander J; Chiang A
Can J Ophthalmol; 2016 Oct; 51(5):342-347. PubMed ID: 27769324
[TBL] [Abstract][Full Text] [Related]
16. Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks.
Sekfali R; Mimoun G; Cohen SY; Querques G; Bandello F; Sacconi R; Souied EH; Capuano V
Eur J Ophthalmol; 2020 May; 30(3):550-556. PubMed ID: 30880436
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U;
Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240
[TBL] [Abstract][Full Text] [Related]
18. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.
Homer N; Grewal DS; Mirza RG; Lyon AT; Gill MK
Eye (Lond); 2015 Sep; 29(9):1152-5. PubMed ID: 26021870
[TBL] [Abstract][Full Text] [Related]
19. Initial utilization of aflibercept in exudative age-related macular degeneration.
Cho H; Weber ML; Shah CP; Heier JS
Eur J Ophthalmol; 2014; 24(4):576-81. PubMed ID: 24706352
[TBL] [Abstract][Full Text] [Related]
20. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]